Progyny, Inc.

A new survey by Progyny found that 71% of people navigating fertility, pregnancy, postpartum, and menopause care experience significant stress, with 43% reporting it impacts work performance. The survey highlighted a strong desire for personalized, human-led healthcare guidance, with over 70% wishing for trusted human support. Progyny's Care Advocates (PCAs) were shown to reduce stress for 60% of members and empower 63% in their healthcare journey. This reinforces the importance of human connection alongside technology in emotional healthcare experiences.

Progyny, Inc. held its 2026 Annual Meeting, where stockholders approved significant amendments to the Certificate of Incorporation and Bylaws. These changes eliminate certain supermajority voting requirements, including those for director removal, bylaw amendments, and specific business combinations, effective May 21, 2026. Additionally, stockholders elected Class I directors, ratified Ernst & Young LLP as the independent auditor, and approved executive compensation on an advisory basis.

Progyny, Inc. announced that its Board of Directors has authorized a share repurchase program for up to $200 million of its common stock. The program will be funded using the company's available cash balances. Repurchases may occur through open market transactions, including Rule 10b5-1 plans, and are subject to market conditions and the company's sole discretion.

Progyny, Inc. announced that its Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat. The event is scheduled for the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. A live audiocast and replay of the presentation will be accessible via the company's investor relations website.

Progyny, Inc. reported strong financial performance for the first quarter of 2026, with net income significantly increasing by 60.9% to $24.2 million and diluted earnings per share rising by 70.6% to $0.29. The company, which specializes in fertility, family building, and women's health benefits solutions, also saw a modest revenue increase of 1.4% to $328.5 million. Additionally, Progyny repurchased $117.7 million of its common stock during the quarter.

Progyny, Inc. announced strong first quarter 2026 financial results, reporting record revenue of $328.5 million, a 1.4% increase year-over-year, or 12.2% excluding a former large client. Net income surged by 60.3% to $24.2 million, while Adjusted EBITDA saw a slight decrease of 2.1% to $56.6 million due to planned platform investments. The company also completed its share repurchase program, buying back 8.8 million shares to date, and provided an optimistic full-year 2026 outlook.

Progyny, Inc. announced it will release its financial results for the first quarter ended March 31, 2026, after the market closes on Thursday, May 7, 2026. The company will host a conference call on the same day at 4:45 p.m. Eastern Time to discuss the results. A press release detailing the financial performance will be issued prior to the call, and an audio replay will be available until May 14, 2026.

Progyny, Inc. announced the launch of Progyny Select, the industry's first fully insured, comprehensive supplemental fertility and family building plan. This new offering aims to expand access to fertility solutions for small employers in the U.S., covering approximately 50 million people. The plan provides predictable costs through a fixed premium model and includes Progyny's value-based care model, managed provider network, Smart Cycle benefit, and personalized member navigation.